ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Identification of a Genomic Region between
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 29% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Efficacy and safety of ramucirumab for gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis.European journal of clinical pharmacology · 2024Pooled it
- VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.Scientific reports · 2022Trial
- Apatinib-Induced Hypertension Correlates with Improved Prognosis in Solid Tumor Patients.Cardiovascular toxicology · 2025Article
- Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825.Neuro-oncology · 2025Article
- Celastrol attenuates hepatitis C virus translation and inflammatory response in mice by suppressing heat shock protein 90β.Acta pharmacologica Sinica · 2023Article
- Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension-Mechanisms and Mitigation.Hypertension (Dallas, Tex. : 1979) · 2023Review
- Bioinformatics Analysis of Next Generation Sequencing Data Identifies Molecular Biomarkers Associated With Type 2 Diabetes Mellitus.Clinical medicine insights. Endocrinology and diabetes · 2023Article
- VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications.Current oncology reports · 2022Review
- Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy.Cancer science · 2020Review
- Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors.Molecular cancer therapeutics · 2020Article
- Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease.Pharmacogenomics and personalized medicine · 2020Review
- Combined Performance of Screening and Variable Selection Methods in Ultra-High Dimensional Data in Predicting Time-To-Event Outcomes.Diagnostic and prognostic research · 2018Article
- Identification of biomarkers, pathways, and potential therapeutic targets for heart failure using next-generation sequencing data and bioinformatics analysis.Therapeutic advances in cardiovascular diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 11 institutions in 2 countries.
Megan LiDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California.
Flora MulkeyAlliance Statistics and Data Center, Duke University, Durham, North Carolina.
Chen JiangAlliance Statistics and Data Center, Duke University, Durham, North Carolina.
Bert H O'NeilDepartment of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
Bryan P SchneiderDepartment of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
Fei ShenDepartment of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
Paula N FriedmanDepartment of Medicine, University of Chicago Comprehensive Cancer, Chicago, Illinois.
Yukihide MomozawaLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan.
Michiaki KuboLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan.
Donna NiedzwieckiAlliance Statistics and Data Center, Duke University, Durham, North Carolina.
Howard S HochsterYale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
Heinz-Josef LenzNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
James N AtkinsSoutheast Clinical Oncology Research Consortium, Winston-Salem, North Carolina.
Hope S RugoDepartment of Medicine, University of California San Francisco, San Francisco, California.
Susan HalabiAlliance Statistics and Data Center, Duke University, Durham, North Carolina.ORCID 0000-0003-4135-2777
William Kevin KellyDepartment of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Howard L McLeodDeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0002-9004-9232
Federico InnocentiCenter for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Mark J RatainDepartment of Medicine, University of Chicago Comprehensive Cancer, Chicago, Illinois.
Alan P VenookDepartment of Medicine, University of California San Francisco, San Francisco, California.
Kouros OwzarAlliance Statistics and Data Center, Duke University, Durham, North Carolina.
Deanna L KroetzDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California. deanna.kroetz@ucsf.edu.
Duke University · USUniversity of California, San Francisco · USIndiana University School of MedicineRIKEN Center for Integrative Medical Sciences · JPUniversity of Chicago · USMoffitt Cancer Center · USSoutheast Clinical Oncology Research Consortium · USThomas Jefferson University · USUniversity of North Carolina at Chapel Hill · USUniversity of Southern California · USYale Cancer Center · US
Funding
Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kate Taylor Shumate · 1999 to 2026
$209.7MECOG-ACRIN NCORP Research Base - TMISTUG1CA189828 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$199.7MMember Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MProject-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6MSWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1MStatistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0MSoutheast Clinical Oncology Research Consortium, Inc. (SCOR)UG1CA189858 · NCI · SOUTHEAST CLINICAL ONCOL RES CONSORTIUM · PI Judith O Hopkins, William J Irvin · 2014 to 2026
$38.8MSOUTHEAST CANCER CONTROL COSORTIUM, INCU10CA045808 · NCI · SOUTHEAST CLINICAL ONCOL RES CONSORTIUM · PI ATKINS, JAMES NORMAN · 1987 to 2013
$26.6MCancer and Leukemia Group B Human Specimen RepositoriesU24CA114725 · NCI · UNIVERSITY OF CHICAGO · PI BERTAGNOLLI, MONICA M · 2005 to 2014
$11.1MPHARMACEUTICAL SCIENCES AND PHARMACOGENOMICST32GM007175 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHITUV, NADAV, KROETZ, DEANNA L · 1985 to 2021
$7.1MCANCER AND LEUKEMIA GROUP B GRANT REVISED APPLICATIONU10CA041287 · NCI · UNIVERSITY OF CHICAGO · PI KINDLER, HEDY L · 1986 to 2013
$3.9MYale Cancer Center NCTNU10CA180826 · NCI · YALE UNIVERSITY · PI FUCHS, CHARLES S · 2014 to 2018
$3.4MNCI NIH HHS P30 CA082103NCI NIH HHS U10 CA041287NCI NIH HHS U10 CA045808NCI NIH HHS U10 CA047559NCI NIH HHS U10 CA047577NCI NIH HHS U10 CA138561NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180826NCI NIH HHS U10 CA180830NCI NIH HHS U10 CA180836NCI NIH HHS U10 CA180838NCI NIH HHS U10 CA180882NCI NIH HHS U10 CA180888NCI NIH HHS U24 CA114725NCI NIH HHS UG1 CA180830NCI NIH HHS UG1 CA189828NCI NIH HHS UG1 CA189858NIGMS NIH HHS F31 GM113350NIGMS NIH HHS T32 GM007175NIH HHS S10 OD018164
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overAngiogenesis InhibitorsBevacizumabClinical Trials as TopicEquilibrative Nucleoside Transporter 1FemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHSP90 Heat-Shock ProteinsHumansHuman Umbilical Vein Endothelial CellsHypertensionMaleMiddle AgedAngiogenesis InhibitorsBevacizumabEquilibrative Nucleoside Transporter 1HSP90AB1 protein, humanHSP90 Heat-Shock ProteinsSLC29A1 protein, humanVascular Endothelial Growth Factor AVEGFA protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.